NPC-02

Phase 3Small molecule

NNobelpharma

NPC-02 is one of 2 small molecule programs targeting Zinc deficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Zinc DeficiencyActive, not recruiting

Zinc DeficiencyPhase 3

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Zinc Deficiency

#DrugCompanyPhaseTrials

NPC-02

NNobelpharma

Phase 3

2 2

Verazinc

FFakultas Kedokteran Universitas Indonesia

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Zinc deficiency2 trials

A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency

Completed·NNobelpharma·Phase 3·NCT02337569·57 enrolled

Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency

Completed·NNobelpharma·Phase 3·NCT02321865·43 enrolled

Efficacy and Safety1 trial

Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.

Completed·NNobelpharma·Phase 3·NCT00212355·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NPC-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NPC-02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NPC-02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nobelpharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNobelpharma

NPC-02

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Zinc deficiency2 trials

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News